NCT07638449尚未招募不适用
A Prospective, Single-Arm Study Evaluating Silkworm Pupa Powder in Improving Alzheimer's Disease Among Patients
Zhejiang Provincial Tongde Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年6月1日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
- 试验地点
- 1
研究概览
简要总结
The goal of this clinical trial is to learn if silkworm pupa powder works to treat Alzheimer's disease in patients. It will also learn about the safety of silkworm pupa powder, and its effect on patients' nutritional and frailty status. The main questions it aims to answer are:
- Does silkworm pupa powder improve cognitive function and daily living abilities?
- Does silkworm pupa powder improve nutritional status and frailty?
- What medical problems do participants have when taking silkworm pupa powder?
Researchers will evaluate the treatment by comparing the participants' conditions after taking the powder to their baseline conditions (a single-arm study without a placebo) to see if silkworm pupa powder works to treat Alzheimer's disease.
Participants will:
- Take silkworm pupa powder every day for 12 weeks
- Visit the clinic once every 4 weeks for checkups and tests
- Use an electronic punch-card system daily and report any symptoms
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of probable Alzheimer's disease (AD) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. Disease severity is classified as mild to moderate, defined as a Mini-Mental State Examination (MMSE) total score of 0-24 points, inclusive, at both screening and baseline.
- •Confirmation of AD pathology per the 2024 revised AD diagnostic criteria (biomarker-defined AD with both Aβ and tau positivity):
- •Aβ positivity: Plasma Aβ42/40 ratio ≤0.08 or amyloid-PET positivity (SUVR ≥1.1).
- •Tau positivity: Plasma p-tau217 ≥2.5 pg/mL (or CSF p-tau181/Aβ42 ratio ≥0.02).
- •Age 50 to 90 years (inclusive), male or female, with at least a primary school education.
- •Stable medication use: If receiving approved AD therapies (e.g., acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists), doses must remain stable for ≥12 weeks prior to baseline. Treatment-naïve participants are also eligible. All other permitted non-AD related concomitant medications must remain stable for ≥4 weeks prior to baseline unless otherwise specified.
- •Hachinski Ischemia Scale (HIS) total score ≤
- •Geriatric Depression Scale-15 (GDS-15) total score ≤
- •Neuroimaging evidence: Screening CT/MRI showing age-related brain changes or cerebral atrophy.
- •Participant has a stable and reliable caregiver, as confirmed by the investigator.
- •Written informed consent must be provided by the participant or, if the participant lacks decision-making capacity, by a legally authorized representative (in accordance with local laws, regulations, and customs). Participants must agree to provide peripheral blood, stool, and urine samples during the study for biomarker analysis.
排除标准
- •Diagnosis of dementia other than Alzheimer's disease (AD) or other central nervous system disorders.
- •Unstable vital signs accompanied by abnormalities in cardiac, pulmonary, hepatic, renal, or other organ functions.
- •Abnormally low folate and/or vitamin B12 levels, or evidence that hypothyroidism has caused or exacerbated the participant's dementia. Abnormal syphilis test results.
- •Comorbid psychiatric disorders.
- •Long-term alcoholism or substance abuse that may compromise the evaluation of treatment efficacy.
- •Intolerance or allergy to the study medication (silkworm pupa powder).
- •Abnormalities detected on cranial MRI, including ischemic or hemorrhagic infarctions, hydrocephalus, or brain tumors.
- •Diagnosis of clinically significant cardiovascular or cerebrovascular disease requiring treatment within 12 months or at present.
- •Geriatric Depression Scale-15 (GDS-15) score >4 at screening.
- •Any other inadequately controlled condition (e.g., cardiac, respiratory, renal, or gastrointestinal disorders affecting absorption, such as gastric cancer, gastric bypass surgery, or recurrent diarrhea) that may jeopardize participant safety or interfere with study assessments, as judged by the investigator.
- •Administration of any new chemical entity in an AD clinical study within 6 months prior to screening.
- •Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or electrocardiogram (ECG) requiring further investigation, treatment, or posing risks to study procedures or safety.
- •Participation in a clinical study involving therapeutic monoclonal antibodies, antibody-derived proteins, immunoglobulin therapy, or vaccines within 6 months prior to screening.
- •Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapy and any BACE inhibitor therapy).
- •Any inadequately controlled immune disorder, or immune disease requiring treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives), systemic immunosuppressants, or plasmapheresis during the study.
- •Inadequately controlled bleeding disorders (including platelet count <50,000 or INR >1.5 for participants not on anticoagulants, e.g., warfarin). Participants on anticoagulants must have their anticoagulation status optimized and receive a stable dose within 4 weeks prior to screening. Participants receiving anticoagulant therapy must not participate in cerebrospinal fluid (CSF) assessments.
- •Participation in another concurrent silkworm pupa powder intervention study conducted at the same study center.
研究者
Jiangtao Zhang
Principal Investigator
Zhejiang Provincial Tongde Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
一项蚕蛹粉剂干预阿尔茨海默病患者营养状况的前瞻性、双盲、随机对照临床研究ChiCTR2500095304自筹
已完成
2 期
Fisetin in Mild Alzheimer's DiseaseAlzheimer DiseaseNCT07279714Sunnybrook Health Sciences Centre5
招募中
1 期
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's DiseaseAlzheimer's DiseaseNCT07599670AbbVie210
Unknown
不适用
诗碧曼延缓阿尔茨海默病患者认知功能障碍的随机双盲临床试验ChiCTR2500099618诗碧曼延缓阿尔茨海默病患者认知功能障碍的随机双盲临床试验 / 连云港诗碧曼生物科技有限公司40
Unknown
不适用
普拉梭菌改善阿尔兹海默症患者认知功能有效性和安全性研究ChiCTR2500105932安徽省卫健委科研项目，普拉梭菌改善阿尔兹海默症患者认知功能随机对照研究，AHWJ2023BAc10004，2023/12-2026/1260